Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 10/2014

01-10-2014 | Erratum

Erratum to: Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine

Authors: Yinin Hu, Gina R. Petroni, Walter C. Olson, Andrea Czarkowski, Mark E. Smolkin, William W. Grosh, Kimberly A. Chianese‑Bullock, Craig L. Slingluff Jr.

Published in: Cancer Immunology, Immunotherapy | Issue 10/2014

Login to get access

Excerpt

Unfortunately, the published version of this article did not include vital grant information. The relevant details are given below. …
Metadata
Title
Erratum to: Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine
Authors
Yinin Hu
Gina R. Petroni
Walter C. Olson
Andrea Czarkowski
Mark E. Smolkin
William W. Grosh
Kimberly A. Chianese‑Bullock
Craig L. Slingluff Jr.
Publication date
01-10-2014
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 10/2014
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-014-1601-4

Other articles of this Issue 10/2014

Cancer Immunology, Immunotherapy 10/2014 Go to the issue

Original Article

A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor

Meeting Report

The Thirteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-13), October 2–4, 2013, Amsterdam, The Netherlands: the current standing of anti-tumor immunotherapeutic approaches

Original Article

Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals

Review

Shaping of an effective immune microenvironment to and by cancer cells

Original Article

Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival—a substudy of the MIMOSA trial

Focussed Research Review

Extracellular adenosine metabolism in immune cells in melanoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits